Exsilio Therapeutics is developing genomic medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions.

Exsilio’s technology is based on naturally occurring genetic elements that can precisely insert new genes into a cell through RNA intermediate templates.

Exsilio uses predictive in silico modeling and wet lab-based experimentation to engineer such elements for precise insertion of therapeutic genes into safe harbor sites of disease-relevant cells.

Because Exsilio’s medicines are encoded in mRNA, they can be delivered using validated, non-viral delivery platforms that are safe, efficient, scalable, and cost-effective, and that allow redosing to effect with a curative intent.